CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 104, Issue 6, Pages 441-451
Publisher
Oxford University Press (OUP)
Online
2012-03-07
DOI
10.1093/jnci/djs125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
- (2011) G. Viale et al. ANNALS OF ONCOLOGY
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
- (2011) Marco Colleoni et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Pharmacogenetics of Endocrine Therapy for Breast Cancer
- (2010) Michaela J. Higgins et al. Annual Review of Medicine
- Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects
- (2010) A Ahmad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues
- (2010) M J Sikora et al. PHARMACOGENOMICS JOURNAL
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
- (2009) N. Lynn Henry et al. BREAST CANCER RESEARCH AND TREATMENT
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Pharmacogenomics of Tamoxifen Therapy
- (2009) H. Brauch et al. CLINICAL CHEMISTRY
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
- (2009) J M Rae et al. PHARMACOGENOMICS JOURNAL
- Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
- (2008) R. S. Punglia et al. JNCI-Journal of the National Cancer Institute
- Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial
- (2008) Jack Cuzick et al. LANCET ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now